Berlin Cures Advances With BC 007 In Long COVID Trial, Over Half Enrolled

Berlin Cures, a biotechnology firm in the clinical stage, has achieved a pivotal point in its Europe-wide clinical trial targeting Long COVID. The company has successfully enrolled more than half of the intended 114 patients. This trial is pivotal in evaluating the effectiveness of BC 007, Berlin Cures' innovative drug aimed at neutralizing functional autoantibodies (fAABs), which are believed to be a significant factor in the persistence of Long COVID symptoms. The study spans across 12 trial centers in countries including Finland, Germany, Austria, Switzerland, and Spain, with plans to expand to another seven centers soon.

Long COVID has emerged as a formidable global health challenge, affecting over 100 million people worldwide. Oliver von Stein, CEO of Berlin Cures, emphasized the company's dedication not only to addressing the virus's lingering effects but also to improving the quality of life for those impacted. The ongoing Phase II clinical trial represents a beacon of hope for many, with results expected by autumn 2024 that could lead to the initiation of a Phase III study essential for regulatory approval.

BC 007 targets harmful fAABs implicated in various autoimmune conditions, including Long COVID. Approximately 40% of Long COVID patients have detectable levels of fAABs in their blood tests. These autoantibodies can mistakenly target the body's tissues or cells following infections, potentially leading to autoimmune diseases. BC 007's approach to neutralizing these fAABs offers a promising solution to combat the underlying cause of Long COVID symptoms in a significant portion of affected individuals.

Advancing Towards a Cure

Berlin Cures is actively seeking additional funding and partnerships to proceed with the crucial Phase III study. The company's commitment to combating diseases caused by fAABs is supported by private funding since its inception. BC 007 not only represents hope for Long COVID patients but also stands as a versatile platform technology with the potential to act against many fAAB-associated diseases.

Proven Efficacy and Safety

The journey of BC 007 from research to clinical trials has demonstrated significant efficacy and safety. In Phase I studies with fAAB-positive volunteers and a Phase IIa trial with heart failure patients, BC 007 showed significant long-term benefits. These results highlight the drug's effective and lasting neutralization of fAABs after treatment, marking it as safe and well-tolerated.

Berlin Cures continues its quest for additional investments and partnerships to advance this groundbreaking opportunity against Long COVID and potentially other autoimmune diseases. The progress of their clinical trial across Europe underscores a collective effort towards finding a cure and restoring health and vitality to millions affected by this condition.